Lauren Madigan, MD, shares open-label extension results demonstrating sustained improvements with avapritinib in patients ...
Long-term data from the PIONEER trial, presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting, support the durability of response with the KIT inhibitor avapritinib ...
There is a promising new drug for the rare disease mastocytosis, which is associated with skin lesions, among other things.
FDA NDA submission for bezuclastinib targets post-imatinib GIST, using Real-Time Oncology Review and supported by prior ...
The KIT inhibitor avapritinib (Ayvakit) maintained symptom improvement and reduced mast cell burden in patients with indolent systemic mastocytosis for an average of 4 years, according to long-term ...
21d
Cogent Biosciences Touts Bezuclastinib Pivotal Wins, Eyes Up to Three FDA Filings and U.S. Launches
CEO Andrew Robbins outlined the company’s transition into a pre-commercial stage at an annual healthcare conference, ...
There is a promising new drug for the rare disease mastocytosis, which is associated with skin lesions, among other things.
Bezuclastinib NDA submitted under the FDA’s RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted ...
Novartis' Rydapt has become the first and only licensed treatment for rare and life-threatening blood disorder systemic mastocytosis (SM) to be cleared for routine NHS use, after getting a green light ...
UBS analysts have outlined a set of high-conviction healthcare ideas where they believed the market was underappreciating ...
This biotechnology firm develops precision therapies for rare, genetically defined diseases, with a focus on targeted cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results